1211-40-1

Basic information

• Product Name: 4-AMINO-4'-NITROBIPHENYL
• Synonyms: 4-(4-Nitrophenyl)aniline;4-Amino-4'-nitro-1,1'biphenyl;4-Nitro-4'-aminobiphenyl;4'-Nitrobiphenyl-4-amine;(4'-nitrobiphenyl-4-yl)amine;[4-(4-nitrophenyl)phenyl]amine;[4-(4-aminophenyl)phenyl]-dihydroxy-amine;4-(4-aminophenyl)-N,N-dihydroxyaniline
• CAS NO: 1211-40-1
• Molecular Formula: C₁₂H₁₀N₂O₂
• Molecular Weight: 214.22
• Product Categories: Reagent for High-Performance Polymer Research;Biphenyls (for High-Performance Polymer Research);Functional Materials;Organic Nonlinear Optical Materials
• Mol File: 1211-40-1.mol
• Article Data: 12

Chemical Properties

• Melting Point: 204°C
• Boiling Point: 354.35°C (rough estimate)
• Flash Point: 188.9 °C
• Appearance: /
• Density: 1.2042 (rough estimate)
• Refractive Index: 1.6660 (estimate)
• PKA: 3.69±0.10(Predicted)
• Stability: Stability
• CAS DataBase Reference: 4-AMINO-4'-NITROBIPHENYL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINO-4'-NITROBIPHENYL(1211-40-1)
• EPA Substance Registry System: 4-AMINO-4'-NITROBIPHENYL(1211-40-1)

Safety Data

• Statements: 20/21/22
• Safety Statements: 22-36/37/39
• RTECS: DV0350000
• HazardClass: IRRITANT
• Hazardous Substances Data: 1211-40-1(Hazardous Substances Data)

Usage

General Description

4-AMINO-4'-NITROBIPHENYL is a chemical compound with the molecular formula C12H10N2O2. It is a nitro-substituted amine that is primarily used as an intermediate in the production of dyes, pigments, and pharmaceuticals. It is classified as a mutagen and a potential human carcinogen, and exposure to this compound is associated with an increased risk of bladder cancer. 4-AMINO-4'-NITROBIPHENYL is a yellow crystalline solid at room temperature and is insoluble in water but soluble in organic solvents. It is important to handle this chemical with caution and to follow proper safety protocols to minimize the risk of exposure and harmful effects.

Upstream product

• 13924-28-2 N-benzylidene-4-phenylaniline 
• 92-87-5 p,p'-diaminobiphenyl 
• 1528-74-1 4,4'-dinitrobiphenyl 
• 7783-06-4 hydrogen sulfide 
• 24067-17-2 4-nitrophenylboronic acid 
• 540-37-4 p-aminoiodobenzene 
• 82481-85-4 N-(4'-nitrobiphenyl-4-yl)benzamide 
• 1093736-99-2 9,10-dihydro-9,10-dimethyl-N-[4-(4-nitrophenyl)phenyl]-9,10-(epoxyimino)anthracene-11-carboxamide 
• 586-78-7 para-nitrophenyl bromide 
• 92-93-3 1-phenyl-4-nitrobenzene 
• 100-00-5 4-chlorobenzonitrile 
• 51-84-3 acetylcholine 
• 7722-84-1 dihydrogen peroxide 
• 135-69-3 4-acetyl-4'-nitrobiphenyl 

Downstream Products

• 3916-44-7 4-(4-nitrophenyl)phenol 
• 6242-98-4 4'-bromo-4-nitrobiphenyl 
• 2578-32-7 4',4'''-azo-bis-biphenyl-4-ylamine 
• 3366-54-9 3-hydroxy-benzidine 
• 92-87-5 p,p'-diaminobiphenyl 
• 690650-40-9 N-(4'-nitro-biphenyl-4-yl)-toluene-4-sulfonamide 
• 871901-25-6 N-(4'-nitro-biphenyl-4-yl)-naphthalene-2-sulfonamide 
• 62-23-7 4-nitro-benzoic acid 
• 372093-27-1 N-[4-(4-Nitrophenyl)phenyl)-(2-chloro-5-nitrophenyl)carboxamide 
• 838852-84-9 (3R)-N-(4'-Nitrobiphenyl-4-yl)quinuclidine-3-carboxamide hydrochloride 
• 2143-90-0 4-methoxy-4'-nitrobiphenyl 

Relevant articles and documents

Electroreductive generation of recyclable organic reductant from N,N′-dioctyl-4,4′-bipyridinium and Pd-catalyzed reductive coupling of aryl halides

Electroreduction of N,N′-dioctyl-4,4′-bipyridinium bis(triflimide) [C8V2+][Tf2N-] 2 in THF gave a dark blue solution of the corresponding quinoid C8V0, which worked as an efficient organic reductant for Pd-catalyzed reductive coupling of aryl bromides to give the corresponding biphenyl derivatives in good yields. After usual workup, [C8V 2+][Tf2N-]2 was recovered and reused for generation of the organic reductant C8V0. Georg Thieme Verlag Stuttgart.

Palladium(II) chloride/EDTA-catalyzed biaryl homo-coupling of aryl halides in aqueous medium in the presence of ascorbic acid

Both electron-deficient and electron-rich aryl bromides undergo biaryl homo-coupling in a basic aqueous-ethanolic medium in the presence of PdCl2-EDTA (1:1 molar ratio, 3 mol %) as catalyst and ascorbic acid as reductant (1 mol equiv) in acceptable to good yields.

-

-

Novel biphenyl tetrazole derivative and preparation method thereof

The invention relates to a novel biphenyl tetrazole derivative. A chemical general molecular formula of the novel biphenyl tetrazole derivative is shown as the accompanying drawing. The invention also relates to a preparation method of the novel biphenyl tetrazole derivative. A synthesis path is shown as the accompanying drawing, wherein n is selected from 0, 1, 2, 3, 4 and 5; Y is selected from -Br, -Cl, -NO2 and a substance shown as the accompanying drawing; R1, R2 and R3 are selected from -H, mono-substituted or poly-substituted -F, -(CH2)mCH3, -(CH2)mCF3, -O(CH2)mCH3, -O(CH2)mCF3 and -NO2 groups; m is selected from 0, 1, 2, 3, 4 and 5. The method comprises the operation steps that a compound II and 1,4-diazido dicyclic [2.2.2] octane are dissolved into a mixed reaction solution of a first organic solvent and carbon disulfide; filtering is performed to obtain yellow solids; after washing drying, the materials are dissolved into a second organic solvent; triphosgene or diphosgene is added; or phosgene reaction is performed; filtering is performed; filter liquid is collected; concentration is performed to obtain a crude product; the crude product is dissolved into a third organic solvent; ammonia water is added; concentration is performed to obtain yellow solid crude products; the solid crude products are dissolved into a four organic solvent; then, NaN3, I2 and organic amine NHpR are sequentially added into the organic solvent; basic water solution is added for quenching reaction; a fifth organic solvent is used for extracting the organic layer; concentration and purification are performed; a compound III is obtained.

WNT PATHWAY MODULATORS

The present invention relates to dihydropyrazolo[l,5-a]pyrimidine compounds of formula I, defined herein, as WNT pathways modulators, processes for making them, and pharmaceutical compositions comprising them. Methods of treatment of conditions mediated by WNT pathway signalling including cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction, comprising the compounds of formula I are also provided.